Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07283705 · ClinicalTrials.gov registry record · Phase 2

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

A Phase 2 study, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target

NCT07283705: Recruiting Phase 2 study, sponsored by M.D. Anderson Cancer Center.

NCT07283705 is a Phase 2 study that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT07283705, a Phase 2 study, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target

Study Summary

To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.

Primary Outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Interventions

  • DRUG Gemcitabine
  • DRUG mFOLFIRINOX
  • DRUG Nab-paclitaxel
  • DRUG BMS-986504

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2026-05-18
Est. Completion 2031-10-01
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What NCT07283705 shows while recruiting

NCT07283705 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).

The record links to 0 conditions, and to 4 interventions - of which Gemcitabine is the first listed.

NCT07283705 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07283705 about?

NCT07283705 is a clinical study titled "A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer". To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.

What is the current status of trial NCT07283705?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-05-18. Estimated completion is 2031-10-01.

What interventions are being tested in trial NCT07283705?

The interventions under investigation include: Gemcitabine (DRUG), mFOLFIRINOX (DRUG), Nab-paclitaxel (DRUG), BMS-986504 (DRUG).

Who is sponsoring clinical trial NCT07283705?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07283705's enrollment target sits among peer trials

60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07283705, the US trial registry maintained by the National Library of Medicine. NCT07283705 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.